In this article
President Donald Trump on Thursday struck landmark deals with Eli Lilly
and Novo Nordisk
that could mark a turning point in how many people can access their costly blockbuster obesity drugs.
Under the agreements, Medicare will start covering GLP-1s for obesity for certain patients for the first time beginning in mid-2026 – a shift that will open access to millions of older adults and could spur more employers and other private insurers to follow suit, some experts said. Novo Nordisk and Eli Lilly are also lowering the prices that all state Medicaid programs will pay for GLP-1s, but it’s up to states to opt into coverage.
